Sotorasib in <i>KRAS</i> p.G12C-Mutated Pulmonary Sarcomatoid Carcinoma: Therapeutic Efficacy of a <i>KRAS</i> Inhibitor in Symptomatic Brain Metastases.

ABSTRACT:

Introduction

Pulmonary sarcomatoid carcinomas (PSCs) are a rare subgroup of non-small cell lung cancer (NSCLC). In contrast to other NSCLCs, PSCs have a poor prognosis due to limited efficacy of radiation and chemotherapy. Therefore, other therapeutic approaches are needed. KRAS mutations occur in PSC with a significant proportion of 30%, and most of them are G12C with the therapeutic option of sotorasib.

Case report

Here, we describe the case of a patient with PSC and pleural metastases. After first-line chemotherapy, the patient presented with new neurological symptoms such as a hemiparesis of the right arm and focal seizures. Following the detection of new brain metastases, we switched the therapy to sotorasib due to the presence of a KRAS G12C mutation. Dur

SUBMITTER: Schmidt JF 

PROVIDER: S-EPMC11521458 | biostudies-literature | 2024 Jan-Dec

REPOSITORIES: biostudies-literature